FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
Clinical trial NCT04699643 · UNKNOWN
Trial details
- NCT number
- NCT04699643
- Sponsor
- EverNov Medicines (Zhuhai Hengqin) Co., Ltd
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-30
- Primary completion
- 2023-06-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.